Rutger M.
- Country
- The Netherlands
- Department
- Nephrology
Research Overview
- Efficacy and Safety of Oral BI 764198 in Adults and Adolescents with Primary or TRPC6-Variant Genetic Focal Segmental Glomerulosclerosis: A Randomized, Placebo-Controlled Trial
- Evaluation of R3R01 for Safety, Tolerability, and Efficacy in Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Data & Insights
Has run more than one trial at 4 of 69 partner sites.
Specializations
Nephrology Focus
The investigator specializes in treating rare kidney disorders, with particular emphasis on Alport Syndrome and Focal Segmental Glomerulosclerosis. Their clinical research centers on innovative therapeutic approaches for these challenging renal conditions.
- Genetic Kidney Disorders
- Glomerular Diseases
- Proteinuria Management
Their work encompasses the evaluation of novel therapeutic agents for rare kidney diseases.
Treatment Resistance
The investigator focuses on addressing steroid-resistant kidney conditions, particularly in the context of FSGS. Their research interests include developing alternative treatment strategies for patients who don't respond to conventional therapies.
- Drug Resistance Patterns
- Alternative Treatment Approaches
- Treatment Optimization
They explore innovative therapeutic options for patients with treatment-resistant kidney disorders.
Clinical Assessment
The investigator specializes in evaluating treatment tolerability and safety profiles in kidney disease interventions. Their expertise includes monitoring therapeutic responses through clinical markers such as proteinuria reduction.
- Safety Assessment
- Treatment Efficacy
- Clinical Biomarkers
Their work involves comprehensive evaluation of therapeutic interventions in rare kidney disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.